Eur J Radiol. 2026 Mar 19;199:112792. doi: 10.1016/j.ejrad.2026.112792. Online ahead of print.
ABSTRACT
OBJECTIVE: This study evaluated whether extending the conventional Stewart ultrasound protocol to include the ankle (ankle-inclusive protocol) improves monosodium urate (MSU) crystal detection in asymptomatic hyperuricemia (AH), compared to further extension with the second metatarsophalangeal joint (MTP2-extended protocol), and whether quantitative crystal burden correlates with subclinical inflammation.
METHODS: In this retrospective single-center study, 94 adults with AH and with no history of clinical gout underwent three ultrasound protocols: Stewart (knees, MTP1), ankle-inclusive (knees, MTP1, ankles), and MTP2-extended (knees, MTP1, ankles, MTP2). MSU crystals and Power Doppler (PD) signals were defined per OMERACT 2021. A novel ankle crystal load score (crystal_score) was developed. Statistical analyses included McNemar’s test, ROC analysis, and multivariable logistic regression.
RESULTS: Adding ankle assessment to the Stewart protocol significantly increased MSU crystal detection by 14.9% (85.1% vs. 70.2%, p < 0.001), whereas subsequent MTP2 addition provided no significant gain (4.3%, p = 0.125). Of the 14 cases detected solely by ankle assessment, the majority (85.7%, 12/14) belonged to the high-risk subgroup (serum uric acid [SUA] ≥ 480 μmol/L), and 28.6% (4/14) exhibited PD signals at the ankle. The crystal_score demonstrated significant discriminative ability for subclinical inflammation (AUC = 0.677, p = 0.003) and was an independent predictor after adjustment (adjusted OR = 1.16 per unit, p = 0.001), particularly in patients with SUA < 480 μmol/L (AUC = 0.709, p = 0.013).
CONCLUSION: Ankle ultrasonography significantly improves MSU crystal detection in AH and should be integrated into screening protocols. The crystal_score has significant discriminative ability as a quantifiable biomarker for subclinical inflammation, especially in patients with SUA < 480 μmol/L, with its moderate correlation (Spearman’s ρ = 0.333) reflecting the “silent deposition” phase of AH. MTP2 assessment can be omitted.These findings support standardized, risk-stratified ultrasound workflows for AH management.
PMID:41921238 | DOI:10.1016/j.ejrad.2026.112792
